![Cynthia Sirard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 31 075 $ in data 31/05/2026
Cynthia Sirard is Chief Medical Officer at Compass Therapeutics, Inc. since 2026.
Formerly, Dr. Sirard was Chief Medical Officer at Cypherpunk Technologies, Inc. from 2020 to 2025 and Medical Director at PAREXEL International Corp.
from 2003 to 2005.
Education includes undergraduate studies at the University of Massachusetts and a doctorate from Chicago Medical School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/04/2026 | 27.500 ( 0,03% ) | 31 075 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COMPASS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2026 |
| Società | Posizione | Fine |
|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. | Direttore Tecnico/Scientifico/R&S | 31/07/2025 |
| PAREXEL INTERNATIONAL CORPORATION | Corporate Officer/Principal | 01/01/2005 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
PAREXEL International Corp.
 PAREXEL International Corp. BiotechnologyHealth Technology Operates as a clinical research organization which provides insights-driven clinical and consulting solutions | Health Technology |
University of Massachusetts
 University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chicago Medical School
 Chicago Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leap Therapeutics, Inc.
 Leap Therapeutics, Inc. BiotechnologyHealth Technology Engages in clinical stage immuno-oncology | Health Technology |
Compass Therapeutics, Inc.
 Compass Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage oncology biopharmaceutical company that develops antibody based therapeutics to treat multiple human diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
